DS 1040

Drug Profile

DS 1040

Alternative Names: DS-1040b; DS1040

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Cardiovascular therapies
  • Mechanism of Action Carboxypeptidase U inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pulmonary embolism; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Stroke in United Kingdom (IV, Infusion)
  • 14 Jun 2017 Daiichi Sankyo plans a phase I trial for Stroke in Japan (JapicCTI-173612)
  • 01 Apr 2017 Phase-I clinical trials in Stroke in Japan (IV) (JapicCTI-173612)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top